Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $12.25

Immunic, Inc. (NASDAQ:IMUX) has earned a consensus rating of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $11.80.

A number of equities research analysts have recently issued reports on IMUX shares. Leerink Partnrs raised shares of Immunic to a “strong-buy” rating in a research report on Monday, September 9th. EF Hutton Acquisition Co. I raised shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. Leerink Partners reaffirmed an “outperform” rating and set a $5.00 target price on shares of Immunic in a report on Monday, September 9th. HC Wainwright started coverage on Immunic in a research note on Monday. They issued a “buy” rating and a $10.00 price target for the company. Finally, B. Riley began coverage on Immunic in a research report on Tuesday, August 27th. They set a “buy” rating and a $6.00 price target on the stock.

Immunic Trading Up 5.3 %

NASDAQ:IMUX opened at $1.20 on Friday. The stock has a 50 day simple moving average of $1.37 and a 200 day simple moving average of $1.34. The stock has a market cap of $108.09 million, a P/E ratio of -0.98 and a beta of 1.88. Immunic has a 1-year low of $0.97 and a 1-year high of $2.11.

Insider Activity

In other Immunic news, Director Richard Alan Rudick purchased 87,300 shares of the firm’s stock in a transaction on Tuesday, November 12th. The stock was purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the transaction, the director now owns 87,300 shares in the company, valued at $100,395. The trade was a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Immunic

Several institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in Immunic in the first quarter valued at approximately $25,000. Jane Street Group LLC boosted its stake in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after purchasing an additional 38,553 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after buying an additional 42,383 shares during the period. State Street Corp raised its stake in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after buying an additional 11,642 shares during the last quarter. Finally, Ikarian Capital LLC lifted its holdings in Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after buying an additional 1,162,378 shares during the period. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.